

**FEDERAL ELECTION COMMISSION****Sunshine Act Meetings**

**TIME AND DATE:** Thursday, January 26, 2023 at 10:30 a.m.

**PLACE:** Hybrid Meeting: 1050 First Street NE, Washington, DC (12th Floor) and Virtual.

*Note:* For those attending the meeting in person, current COVID-19 safety protocols for visitors, which are based on the CDC COVID-19 community level in Washington, DC, will be updated on the Commission's contact page by the Monday before the meeting. See the contact page at <https://www.fec.gov/contact/>. If you would like to virtually access the meeting, see the instructions below.

**STATUS:** The January 26, 2023 Open Meeting has been canceled.

**CONTACT PERSON FOR MORE INFORMATION:** Judith Ingram, Press Officer, Telephone: (202) 694-1220

Individuals who plan to attend in person and who require special assistance, such as sign language interpretation or other reasonable accommodations, should contact Laura E. Sinram, Secretary and Clerk, at (202) 694-1040, at least 72 hours prior to the meeting date.

(Authority: Government in the Sunshine Act, 5 U.S.C. 552b.)

**Laura E. Sinram,**

*Secretary and Clerk of the Commission.*

[FR Doc. 2023-01420 Filed 1-20-23; 11:15 am]

**BILLING CODE 6715-01-P**

**FEDERAL RESERVE SYSTEM****Formations of, Acquisitions by, and Mergers of Bank Holding Companies**

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained

on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)).

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than February 23, 2023.

*A. Federal Reserve Bank of St. Louis* (Holly A. Rieser, Senior Manager) P.O. Box 442, St. Louis, Missouri 63166-2034. Comments can also be sent electronically to

[Comments.applications@stls.frb.org](mailto:Comments.applications@stls.frb.org):

1. *MO/ARK Bancshares, Inc., Hollister, Missouri*; to become a bank holding company by acquiring Stone Bancshares, Inc., and thereby indirectly acquiring Stone Bank, both of Mountain View, Arkansas.

Board of Governors of the Federal Reserve System.

**Michele Taylor Fennell,**

*Deputy Associate Secretary of the Board.*

[FR Doc. 2023-01369 Filed 1-23-23; 8:45 am]

**BILLING CODE P**

**FEDERAL RESERVE SYSTEM****Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company**

The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than February 8, 2023.

*A. Federal Reserve Bank of Minneapolis* (Stephanie Weber, Assistant Vice President); 90 Hennepin Avenue, Minneapolis, Minnesota 55480-0291; Comments can also be sent electronically to [MA@mpls.frb.org](mailto:MA@mpls.frb.org):

1. *James A. Babcock Revocable Trust, James A. Babcock and Marisela Babcock, as co-trustees, all of Elk River, Minnesota*; to join the Babcock Family Shareholder Group, a group acting in concert; to acquire voting shares of Metro North Bancshares, Inc., and thereby indirectly acquire voting shares of the Bank of Elk River, both of Elk River, Minnesota.

*B. Federal Reserve Bank of Kansas City* (Jeffrey Imgarten, Assistant Vice President); 1 Memorial Drive, Kansas City, Missouri 64198.

1. *Scherry Hermansen, St. Libory, Nebraska; Aaron Chochon, Syracuse, Nebraska; David Chochon, Dakota Dunes, South Dakota; Bryan Chochon, Brett Mueller, Sharyn Mueller, and Pamela Mueller, all of Columbus, Nebraska; and the Brooke Allison Mueller Irrevocable Trust, Michael Blanchard, trustee, Benbrook, Texas*; to join the Chochon-Mueller Control Group, a group acting in concert, to retain voting shares of Rae Valley Financials, Inc., and thereby indirectly retain voting shares of Great Plains State Bank, both of Petersburg, Nebraska.

Board of Governors of the Federal Reserve System.

**Michele Taylor Fennell,**

*Deputy Associate Secretary of the Board.*

[FR Doc. 2023-01368 Filed 1-23-23; 8:45 am]

**BILLING CODE P**

**UNITED STATES AGENCY FOR GLOBAL MEDIA****USAGM FY 2022 Service Contract Analysis & FY 2021 Service Contract Inventory**

**AGENCY:** United States Agency for Global Media.

**ACTION:** Notice.

**SUMMARY:** The United States Agency for Global Media (USAGM) announces the members of its FY 2022 Service Contract Analysis and FY 2021 Service Contract Inventory.

**ADDRESSES:** USAGM Office of Contracts, 330 Independence Ave. SW, Washington, DC 20237.

**FOR FURTHER INFORMATION CONTACT:** Khilena Adhin, Acquisition Policy Branch Chief, at [conpolicy@usagm.gov](mailto:conpolicy@usagm.gov), 202-920-2302.

**SUPPLEMENTARY INFORMATION:** In accordance with Section 743 of Division C of the Consolidated Appropriations Act of 2010, the U.S. Agency for Global Media (USAGM) is publishing this notice to advise the public of the availability of its FY 2022 Service Contract Analysis and FY 2021 Service Contract Inventory. They are available on the USAGM website, through the following link: <https://www.usagm.gov/ourwork/strategy-and-results/strategic-priorities/research-reports/service-contract-inventory/>.

The service contract inventory provides information on service contract actions over \$25,000 made in FY 2021. The information is organized by function to show how contracted resources are distributed throughout the Agency. The inventory has been developed in accordance with guidance on service contract inventories issued on November 5, 2010 and on December 19, 2011 by the Office of Management and Budget, Office of Federal Procurement Policy (OFPP).

Dated: January 18, 2023.

**Armanda Matthews,**  
Program Support Specialist, U.S. Agency for Global Media.

[FR Doc. 2023-01322 Filed 1-23-23; 8:45 am]

**BILLING CODE 8610-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Medicare & Medicaid Services

[Document Identifiers: CMS-10844]

#### Agency Information Collection Activities: Proposed Collection; Comment Request

**AGENCY:** Centers for Medicare & Medicaid Services, Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information (including each proposed

extension or reinstatement of an existing collection of information) and to allow 60 days for public comment on the proposed action. Interested persons are invited to send comments regarding our burden estimates or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

**DATES:** Comments must be received by March 27, 2023.

**ADDRESSES:** When commenting, please reference the document identifier or OMB control number. To be assured consideration, comments and recommendations must be submitted in any one of the following ways:

1. *Electronically.* You may send your comments electronically to <http://www.regulations.gov>. Follow the instructions for "Comment or Submission" or "More Search Options" to find the information collection document(s) that are accepting comments.

2. *By regular mail.* You may mail written comments to the following address: CMS, Office of Strategic Operations and Regulatory Affairs, Division of Regulations Development, Attention: Document Identifier/OMB Control Number: \_\_\_\_\_, Room C4-26-05, 7500 Security Boulevard, Baltimore, Maryland 21244-1850.

To obtain copies of a supporting statement and any related forms for the proposed collection(s) summarized in this notice, please access the CMS PRA website by copying and pasting the following web address into your web browser: <https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing>.

**FOR FURTHER INFORMATION CONTACT:** William N. Parham at (410) 786-4669.

#### SUPPLEMENTARY INFORMATION:

##### Contents

This notice sets out a summary of the use and burden associated with the following information collections. More detailed information can be found in each collection's supporting statement and associated materials (see **ADDRESSES**).

CMS-10844 Small Biotech Exception  
Under the PRA (44 U.S.C. 3501-3520), federal agencies must obtain

approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. The term "collection of information" is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA requires federal agencies to publish a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, CMS is publishing this notice.

#### Information Collection

1. *Type of Information Collection Request:* New collection (Request for a new OMB control number); *Title of Information Collection:* Small Biotech Exception; *Use:* Under the authority in sections 11001 and 11002 of the Inflation Reduction Act of 2022 (Pub. L. 117-169), the Centers for Medicare & Medicaid Services (CMS) is implementing the Medicare Drug Price Negotiation Program, codified in sections 1191 through 1198 of the Social Security Act (the Act). In accordance with section 1192(d)(2) of the Act, the term "negotiation-eligible drug" excludes, with respect to the initial price applicability years 2026, 2027, and 2028, a qualifying single source drug that meets the requirements for the exception for small biotech drugs (the "Small Biotech Exception").

This information is required in order for CMS to accurately identify whether a given drug meets the criteria for the Small Biotech Exception in accordance with section 1192(d)(2) of the Act. To ensure that only covered Part D drugs that meet the requirements for the Small Biotech Exception are excluded from the term "negotiation-eligible drug," a manufacturer that seeks the Small Biotech Exception for its covered Part D drug ("Submitting Manufacturer") must submit information to CMS about the company and its products in order for the drug to be considered for the exception. If the Submitting Manufacturer seeks the Small Biotech Exception for a covered Part D drug it acquired after December 31, 2021, the Submitting Manufacturer must also submit information related to the separate entity that had the Medicare Coverage Gap Discount Program agreement for the drug on December 31, 2021. The Information Collection Request Form for the Small Biotech